AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy
This move aims to bolster AstraZeneca’s cardiovascular portfolio in addressing key risk factors associated with chronic cardiovascular diseases. As per the agreement terms, AstraZeneca will gain access to